Home
  >  
Section 69

EurekaMag Full Text Articles Chapter 68,041



References:

Johansson, D.C. 1992: Knee Extensor Performance in Runners. Sports Medicine 14(2): 75-81
Phillip Bishop, M.M. 1993: Blood Lactate Measurement in Recovery as an Adjunct to Training. Sports Medicine 16(1): 5-13
DrMichael S.Bahrke, B.S.H. 1993: Effects of Altitude on Mood, Behaviour and Cognitive Functioning. Sports Medicine 16(2): 97-125
Huub M.Toussaint, A.P.H. 1994: Energetics of Competitive Swimming. Sports Medicine 18(6): 384-405
Michael S.Conley, M.H.S. 1996: Carbohydrate Ingestion/Supplementation for Resistance Exercise and Training. Sports Medicine 21(1): 7-17
Billat, L.V. ©ronique; Koralsztein, J.P. 1996: Significance of the Velocity at VO2maxand Time to Exhaustion at this Velocity. Sports Medicine 22(2): 90-108
Laursen, P.B.; Jenkins, D.G. 2002: The Scientific Basis for High-Intensity Interval Training. Sports Medicine 32(1): 53-73
Urhausen, A.; Kindermann, W. 2002: Diagnosis of Overtraining. Sports Medicine 32(2): 95-102
Wideman, L.; Weltman, J.Y.; Hartman, M.L.; Veldhuis, J.D.; Weltman, A. 2002: Growth Hormone Release During Acute and Chronic Aerobic and Resistance Exercise. Sports Medicine 32(15): 987-1004
Tomkinson, G.R.; L??ger, L.A.; Olds, T.S.; Cazorla, G. 2003: Secular Trends in the Performance of Children and Adolescents (19802000). Sports Medicine 33(4): 285-300
Coris, E.E.; Ramirez, A.M.; Van Durme, D.J. 2004: Heat Illness in Athletes. Sports Medicine 34(1): 9-16
Burfoot, A. 2007: The History of the Marathon. Sports Medicine 37(4-5): 284-287
Lieberman, D.E.; Bramble, D.M. 2007: The Evolution of Marathon Running. Sports Medicine 37(4-5): 288-290
Tunstall Pedoe, D.S. 2007: Marathon Medical Support Historical Perspectives. Sports Medicine 37(4-5): 291-293
Foster, C.; Lucia, A. 2007: Running Economy. Sports Medicine 37(4-5): 316-319
Brooks, G.A. 2007: Lactate. Sports Medicine 37(4-5): 341-343
Burke, L.M. 2007: Nutrition Strategies for the Marathon. Sports Medicine 37(4-5): 344-347
Schwellnus, M.P. 2007: Muscle Cramping in the Marathon. Sports Medicine 37(4-5): 364-367
Eichner, E.R. 2007: Blood Doping. Sports Medicine 37(4-5): 389-391
Maughan, R.J.; Watson, P.; Shirreffs, S.M. 2007: Heat and Cold. Sports Medicine 37(4-5): 396-399
Raglin, J.S. 2007: The Psychology of the Marathoner. Sports Medicine 37(4-5): 404-407
O???Connor, P.J. 2007: Monitoring and Titrating Symptoms. Sports Medicine 37(4-5): 408-411
??kerstr??m, T.??rnC.A.; Pedersen, B.K. 2007: Strategies to Enhance Immune Function for Marathon Runners. Sports Medicine 37(4-5): 416-419
Scott, R.A.; Pitsiladis, Y.P. 2007: Genotypes and Distance Running. Sports Medicine 37(4-5): 424-427
Pyne, S. 2007: Intravenous Fluids Post Marathon. Sports Medicine 37(4-5): 434-436
Thompson, P.D. 2007: Cardiovascular Adaptations to Marathon Running. Sports Medicine 37(4-5): 444-447
Tunstall Pedoe, D.S. 2007: Marathon Cardiac Deaths. Sports Medicine 37(4-5): 448-450
Noakes, T.D. 2007: Hydration in the Marathon. Sports Medicine 37(4-5): 463-466
Ryan, M.; Bond, C. 1994: Dispensing Physicians and Prescribing Pharmacists. PharmacoEconomics 5(1): 8-17
Maiing, T.J.B. 1994: The New Zealand Preferred Medicines Concept. PharmacoEconomics 6(1): 5-14
Richard B.Lipton, W.F.S.,M.V.K 1994: The Burden of Migraine. PharmacoEconomics 6(3): 215-221
Sanford Schwartz, P.J. 1995: Necessity of Using Intermediate Outcomes to Proxy Long Term Effects. PharmacoEconomics 7(1): 7-13
Pouvourville, D.G.érardde 1995: Preventing Nsaid-Induced Gastrointestinal Toxicity. PharmacoEconomics 7(2): 99-110
DrPierre Van Damme, P.B. 1996: Economic Evaluation of Vaccination. PharmacoEconomics 9(3 Suppl): 8-15
Max, D.W. 1996: The Cost of Alzheimers Disease. PharmacoEconomics 9(1): 5-10
DrGeorge E.Ralston, P.W. 1996: Methadone Programmes. PharmacoEconomics 10(4): 321-326
DrRobert M.Kaplan, L.J.S. 1997: Healthcare Resource Consumption in Terminal Care. PharmacoEconomics 11(1): 2-12
DrErik Nord, F.W.øff,M.H.,J.W. 1997: Cost-Utility Analysis of Melphalan plus Prednisone With or Without Interferon-2b in Newly Diagnosed Multiple Myeloma. PharmacoEconomics 12(1): 89-103
DrSheila R.Shulman, M.M. 1997: The Us Orphan Drug Programme. PharmacoEconomics 12(3): 312-326
Rachel H.Foster, K.L.G. 1998: Risperidone. PharmacoEconomics 14(1): 97-133
Rachel H.Foster, G.L.P. 1999: Donepezil. PharmacoEconomics 16(1): 99-114
Tan, D.H.L. 2000: Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model. PharmacoEconomics 17(1): 77-107
DrKenneth J.Smith, M.S.R. 2000: Antiviral Therapies for Herpes Zoster Infections. PharmacoEconomics 18(2): 95-104
Susan C.Wood, V.H.N.,C.S. 2000: Economic Evaluations of Influenza Vaccination in Healthy Working-Age Adults. PharmacoEconomics 18(2): 173-183
DrT.V.Parasuraman, K.F.,J.R. 2001: Enteroviral Meningitis. PharmacoEconomics 19(1): 3-12
J.Caro, J.J.A.O.'B.,K.M.W.… 2001: Economic Analysis of Initial Hiv Treatment. PharmacoEconomics 19(1): 95-104
DrVijay N.Joish, E.P.A. 2001: Which Antifungal Agent for Onychomycosis?. PharmacoEconomics 19(10): 983-1002
C.Daniel Mullins, J.W. 2002: Pharmacy Benefit Management. PharmacoEconomics 20(1): 9-21
Professor Mark Sculpher, D.M.,D.M.,L.P. 2002: Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine. PharmacoEconomics 20(2): 91-100
Christopher J.Dunn, G.L.P. 2002: Insulin Lispro. PharmacoEconomics 20(14): 989-1025
DrJosephine Mauskopf, F.R.,W.S. 2003: Cost-effectiveness league tables. PharmacoEconomics 21(14): 991-1000
Howard G.Birnbaum, S.A.L.,E.F.O.… 2004: Cost of Stress Urinary Incontinence. PharmacoEconomics 22(2): 95-105
Joanne J.Orrick, R.S.,T.E.J.,W.R.… 2004: Resource Use and Cost of Care for Patients Hospitalised with Community Acquired Pneumonia. PharmacoEconomics 22(11): 751-757
DrYves A.Flori, M.leV. 2004: Use and cost of antiretrovirals in France 19952000. PharmacoEconomics 22(16): 1061-1070
Denis Getsios, W.E.H.,I.C.,D.J.J.C. 2005: Pharmacological management of overactive bladder. PharmacoEconomics 23(10): 995-1006
Diane K.Wysowski, L.A.G.,J.S. 2006: Trends in Outpatient Prescription Drug Use and Related Costs in the Us. PharmacoEconomics 24(3): 233-236
Laura Bojke, M.S.,R.S.,W.Q.… 2006: Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer. PharmacoEconomics 24(5): 443-452
DrJulie M.Donohue, H.A.P. 2007: Reducing the Societal Burden of Depression. PharmacoEconomics 25(1): 7-24
Christine M.McDonough, D.A.N.A.T. 2007: Measuring Preferences for Cost-Utility Analysis. PharmacoEconomics 25(2): 93-106
Oren Shavit, M.L.,A.G.,A.S.… 2007: Its Time to Choose the Study Design!. PharmacoEconomics 25(11): 903-911
Denis Getsios, K.M.W.,D.J.J.C. 2007: Nice Cost-Effectiveness Appraisal of Cholinesterase Inhibitors. PharmacoEconomics 25(12): 997-1006
Giovanni Fattore, P.C.J. 2008: The Last Decade of Italian Pharmaceutical Policy. PharmacoEconomics 26(1): 5-15
DrMei Sheng Duh, J.R.W.,L.A.W.… 2008: Management of Anaemia. PharmacoEconomics 26(2): 99-120